The Relationship Between Baseline Body Weight and Glycemic Control Following Metformin Extended-Release Tablets (Glucophage XR) Monotherapy in Chinese Patients With Newly Diagnosed Type 2 Diabetes.

Trial Profile

The Relationship Between Baseline Body Weight and Glycemic Control Following Metformin Extended-Release Tablets (Glucophage XR) Monotherapy in Chinese Patients With Newly Diagnosed Type 2 Diabetes.

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Aug 2013

At a glance

  • Drugs Metformin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 14 Apr 2011 Actual end date (1 Mar 2011) added as reported by ClinicalTrials.gov.
    • 14 Apr 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Jul 2010 Planned end date changed from 1 Jan 2011 to 1 Jan 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top